Werewolf Therapeutics, Inc.
HOWLNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for HOWL. That does not mean none is planned.
Get an email about HOWL's next catalysts
Track Werewolf Therapeutics (HOWL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
HOWL Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
WTX-330 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Werewolf Therapeutics, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Werewolf Therapeutics, Inc.'s (HOWL) pipeline across Phase 2. Its lead program is WTX-330 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Werewolf Therapeutics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Werewolf Therapeutics, Inc. (HOWL) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track HOWL biotech catalysts?β
Add HOWL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Werewolf Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
